ELIZA

return kwic search for response out of >500 occurrences
343831 occurrences (No.54 in the rank) during 5 years in the PubMed. [cache]

289) Using syngeneic IL-1B/IL1R1 knock out mouse models in combination with genetic manipulation of tumour cells to overexpress IL-1B/IL1R1, we found that IL-1B signalling elicited an opposite response in primary tumours compared with bone metastases.

--- ABSTRACT ---

PMID:34290237 DOI:10.1038/s41523-021-00305-w

2021 NPJ breast cancer

* IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer.

- Breast cancer bone metastasis is currently incurable, ~75% of patients with late-stage breast cancer develop disease recurrence in bone and available treatments are only palliative. We have previously shown that production of the pro-inflammatory cytokine interleukin-1B (IL-1B) by breast cancer cells drives bone metastasis in patients and in preclinical in vivo models. In the current study, we have investigated how IL-1B from tumour cells and the microenvironment interact to affect primary tumour growth and bone metastasis through regulation of the immune system, and whether targeting IL-1 driven changes to the immune response improves standard of care therapy for breast cancer bone metastasis. Using syngeneic IL-1B/IL1R1 knock out mouse models in combination with genetic manipulation of tumour cells to overexpress IL-1B/IL1R1, we found that IL-1B signalling elicited an opposite response in primary tumours compared with bone metastases. In primary tumours, IL-1B inhibited growth, by impairing the infiltration of innate immune cell subsets with potential anti-cancer functions but promoted enhanced tumour cell migration. In bone, IL-1B stimulated the development of osteolytic metastases. In syngeneic models of breast cancer, combining standard of care treatments (Doxorubicin and Zoledronic acid) with the IL-1 receptor antagonist Anakinra inhibited both primary tumour growth and metastasis. Anakinra had opposite effects on the immune response compared to standard of care treatment, and its anti-inflammatory signature was maintained in the combination therapy. These data suggest that targeting IL-1B signalling may provide a useful therapeutic approach to inhibit bone metastasis and improve efficacy of current treatments for breast cancer patients.

--- ABSTRACT END ---

[
right
kwic]

[frequency of next (right) word to response]

(1)170 to	(11)5 rates	(21)2 although	(31)2 profiles
(2)56 null	(12)5 with	(22)2 are	(32)2 regulator
(3)27 and	(13)3 at	(23)2 bias,	(33)2 relationship
(4)21 of	(14)3 bias	(24)2 burden	(34)2 surface
(5)20 in	(15)3 genes	(25)2 compared	(35)2 theory
(6)11 was	(16)3 the	(26)2 curve	(36)2 time
(7)8 that	(17)3 through	(27)2 during	(37)2 when
(8)7 is	(18)3 were	(28)2 from
(9)5 by	(19)2 (UPR)	(29)2 observed
(10)5 rate	(20)2 across	(30)2 our

add keyword

--- WordNet output for response --- =>反応, 応答, 返答, 返報, 反響, 答唱句 Overview of noun response The noun response has 7 senses (first 5 from tagged texts) 1. (11) response -- (a result; "this situation developed in response to events in Africa") 2. (11) reaction, response -- (a bodily process occurring due to the effect of some antecedent stimulus or agent; "a bad reaction to the medicine"; "his responses have slowed with age") 3. (6) answer, reply, response -- (a statement (either spoken or written) that is made to reply to a question or request or criticism or accusation; "I waited several days for his answer"; "he wrote replies to several of his critics") 4. (4) reception, response -- (the manner in which something is greeted; "she did not expect the cold reception she received from her superiors") 5. (1) response -- (a phrase recited or sung by the congregation following a versicle by the priest or minister) 6. reply, response -- (the speech act of continuing a conversational exchange; "he growled his reply") 7. response -- (the manner in which an electrical or mechanical device responds to an input signal or a range of input signals) --- WordNet end ---